AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.
Article coming soon This page is under preparation and will be available soon.
About the project
EstPortal.com (Aesthetic Portal) – is a professional resource dedicated to beauty. The project will be of interest to both beauty industry specialists and its connoisseurs. The aim of the project: to provide maximum time saving on search of necessary information for beauty industry specialists and site visitors.